REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /
NCT ID: NCT05372679
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
25 participants
INTERVENTIONAL
2022-11-11
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The current first-line therapy for hypertension involves change in life-style (i.e., diet and exercise) and various medications. However, only about 1 in 4 treated adults (24%) with hypertension have their condition under control. Thus, they are at increased risk for the major side effects of chronically elevated blood pressure, myocardial infarction, stroke, renal disease and heart failure. High blood pressure was a primary or contributing cause of death for more than 494,873 people in the United States in 2018, and was estimated to affect around 1.13 billion people worldwide and resulted in approximately 10 million deaths worldwide, in 2015.
About half of adults (45%) with uncontrolled hypertension have a blood pressure of 140/90 mm Hg or higher, now defined as Stage 2 hypertension. This includes 37 million U.S. adults. About 30 million adults are recommended to take medication. Almost two out of three of this group (19 million) have a blood pressure of 140/90 mm Hg or higher. The other 17 million adults are taking medications but are unable to lower their blood pressure below 140/90 mm Hg and are thus at increased risk for the risks associated with uncontrolled high blood pressure9. High blood pressure costs the United States about $131 billion each year, averaged over 12 years from 2003 to 2014.
In the past decade, several devices were developed in order to target the autonomic nervous system and lower BP in patients with uncontrolled hypertension. These devices aim to provide additional treatment option for patients who do not respond to antihypertensive medication. These devices target other BP regulating mechanisms such as baroreflex activation, deep brain stimulation carotid body ablation, direct vagus nerve stimulation, cardiac neuromodulation, central iliac arteriovenous coupler as well as other devices are currently under research, however, there is no medical device that has been approved so far.
The Therapeutic Intra Vascular UltraSound (TIVUS™) System is designed for renal artery nerve ablation using transluminal ultrasound (US). The TIVUS™ System is a high intensity, non-focused, ultrasound catheter system, which enables remote, localized, controlled, and repeatable thermal modulation of nerves adjacent to arterial vessel wall for performing safe and effective therapeutic artery sympathetic denervation. The ultrasonic energy is transmitted from a catheter positioned within the artery lumen, while avoiding direct contact with the artery wall.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Renal denervation
Denervating the sympathetic nerves surrounding the renal vasculature using unfocused ultrasound
Renal denervation
The TIVUS system will be used for renal denervation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Renal denervation
The TIVUS system will be used for renal denervation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female, ≥ 18 years of age and ≤ 80 years of age at the time of screening.
3. Individual has office systolic blood pressure (SBP) ≥ 140 mm Hg but \< 180 mm Hg, and a diastolic blood pressure (DBP) ≥ 90 mm Hg but \< 110 mm Hg based on an average of 3 office seated blood pressure readings measured by a manual, automated or semi-automated validated BP monitor, on current medications. 4. Documented mean daytime ABPM systolic blood pressure (SBP) ≥ 135 mm Hg but \< 180 mm Hg, after a 4 week stabilization period.
5\. Patient is either on at least one anti-hypertensive medication at maximal tolerated dose with a medically documented intolerance to one or more medications, or on three medications where one is a diuretic.
6\. Patient is willing and expected to maintain their anti-hypertensive medication regimen for at least 3 months.
7\. Patient is able and willing to comply with all study procedures.
Exclusion Criteria
3. Patient has an estimated glomerular filtration rate (eGFR) of \< 40mL/min/1.73m2 CKD-EPI as calculated using the CKD-EPI 2021 equation.
4. Patients with uncontrolled rapid AF.
5. Patient has had a previous renal denervation procedure.
6. Patients with daytime ABPM mean systolic blood pressure (SBP) \> 180 mm Hg.
7. Patient has Type 1 diabetes or poorly controlled Type 2 diabetes (HbA1c \> 9%).
8. Patients with history of myocardial infarction, unstable angina pectoris, heart failure, cerebrovascular accident, or widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques.
9. Patient has a planned major surgery or cardiovascular intervention in the next 6 months.
10. Patient who has undergone a major surgery or cardiovascular intervention in the previous 3 months.
11. Patient has frequent intermittent or chronic pain that results in treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.
12. Patient is taking immunosuppressive therapy for diseases featuring vasculitis.
13. Patient on anticoagulant therapy that cannot be temporarily withheld for study procedure.
14. Contraindication to recommended denervation procedure medications or intravascular contrast that cannot be adequately controlled with pre-medication.
15. Concurrent enrollment in another device or drug trial that has not completed the primary endpoint or clinically interferes with the current study endpoints. For patient previously participating in a drug trial, allow a wash-off period of at least 5 half-lives of the investigational drug.
16. Patient with significant co-morbid condition(s) which, at the discretion of the PI, are deemed to prohibit study entry.
17. Patient works the night shift.
18. Patient has valvular stenosis with risk of cardiac event with significant and/or abrupt decline in systolic blood pressure.
19. Untreated secondary cause of hypertension.
20. Device therapy within the past five years for the treatment of hypertension.
21. Prior renal stent or angioplasty.
22. Life expectancy \<1 year.
23. Patients with history of renal transplant or planned renal transplantation within the next year.
24. History of one or more episodes of severe orthostatic hypotension within the past year.
25. Patient has unstable cardiac or pulmonary disease (including pulmonary hypertension) requiring chronic oxygen support.
26. Uncontrolled or inadequately treated bleeding diathesis.
27. Evidence of active infection within 7 days of procedure
The following characteristics identified either on the renal artery CT scan or on the Eligibility II Renal artery Angiogram will prevent the patient from being included:
1. Main renal arteries \< 4 mm in lumen diameter or \< 20 mm in length; accessory renal arteries, if present, \< 4 mm in lumen diameter or \<10 mm in length.
2. Aorto-renal angle that in the operator's opinion prevents a safe cannulation of the renal artery.
3. Severe common femoral artery, common and/or external iliac artery, renal, iliac or aortic calcification or tortuosity that may compromise the safe performance and completion of the TIVUS™ procedure.
4. Hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which, in the operator's opinion, would interfere with safe cannulation of the renal artery or meets local standards for surgical repair or interventional dilation (NOTE: vessel areas with calcification and fibromuscular dysplasia (FMD) should be avoided as intended treatment areas).
5. Any renal artery stenosis \> 30% by visual assessment.
6. Any renal artery aneurysm (\>50% of the main renal artery reference vessel diameter by visual estimate).
7. Presence of fibromuscular dysplasia
8. Significant renal artery atheroma, aneurysm, calcification in the target vessel identified on CT Angiogram
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SoniVie Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ajay Kirtane, MD
Role: PRINCIPAL_INVESTIGATOR
Columbia University/NYPH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology P.C.
Birmingham, Alabama, United States
ST Bernards Medical Center
Jonesboro, Arkansas, United States
Arkansas Heart Hospital
Little Rock, Arkansas, United States
Bridgeport Hospital
Bridgeport, Connecticut, United States
Prairie Education and Research Cooperative
Springfield, Illinois, United States
Minneapolis Heart Institution Foundation
Minneapolis, Minnesota, United States
Columbia University/NYPH
New York, New York, United States
NC Heart and Vascular Research, LLC
Raleigh, North Carolina, United States
Medical University South Carolina
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLNS05-001
Identifier Type: -
Identifier Source: org_study_id